MedTrade, Crewe, UK has obtained European Union Class 3 Medical device CE approval for Celox, the company's life-saving haemostat (blood clotting agent).
Celox rapidly controls moderate to severe bleeding from arterial, deep arterial or high flow sites within seconds of application by attracting red blood cells to its surface and forming a strong gel plug, which seals the wound.
Since its introduction to the US market in 2006 Celox's ability to rapidly clot blood has made it a popular choice for US special forces and with police, fire departments and ambulance crews in dealing with life threatening incidents.
The material has been demonstrated to rapidly and reliably stop major bleeding in major wounds whether occurring on the battlefield, through knife lacerations, gunshots or from a work related incidents.
CE approval provides European military services, police, emergency and paramedic teams with the same invaluable tool to help save lives across society.
Craig Hardy, ceo of MedTrade, said: "Celox received an outstanding reception following its introduction to the American market. We are therefore thrilled to be able to offer Celox to medics, first responders and safety crews across Europe in their daily fight to save lives.